Physician profile
Ian A Meyer
NPI 1083836043
$5,310.54
in general payments reported to CMS, 2019-2025
29 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $388 · 2021: $564 · 2022: $889 · 2023: $749 · 2024: $930 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,826 · Education: $14.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,826.10 |
| Education | $14.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $747.38 | 2019-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $690.63 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $473.13 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $451.42 | 2019-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $430.91 | 2019-2025 | Velphoro, Velphoro |
| Daiichi Sankyo INC. | $252.12 | 2019-2025 | Injectafer |
| Akebia Therapeutics INC | $207.02 | 2019-2023 | Auryxia |
| Aurinia Pharma U.S., INC. | $204.18 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals Lp | $179.25 | 2019-2025 | Farxiga |
| Travere Therapeutics, INC. | $176.33 | 2019-2025 | |
| Horizon Therapeutics Plc | $162.87 | 2019-2023 | Krystexxa |
| Ardelyx, INC. | $162.82 | 2024-2025 | Ibsrela |
| Mallinckrodt Enterprises LLC | $160.54 | 2019 | |
| Calliditas Therapeutics US INC. | $159.04 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $135.81 | 2020-2025 | Terlivaz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $114.44 | 2019-2024 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.05 | 2023-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $87.96 | 2021-2024 | Oxlumo |
| Novartis Pharmaceuticals Corporation | $81.55 | 2023-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $74.03 | 2019-2024 | |
| Glaxosmithkline, LLC. | $47.56 | 2021-2023 | Benlysta |
| Renalytix Ai, INC. | $39.86 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Lundbeck LLC | $29.79 | 2020 | |
| Pharmacosmos Therapeutics INC. | $29.78 | 2021 | |
| Ani Pharmaceuticals, INC. | $27.35 | 2022 | |
| Alexion Pharmaceuticals, INC. | $26.20 | 2024 | Ultomiris |
| Ultragenyx Pharmaceutical INC. | $25.28 | 2023 | |
| Apellis Pharmaceuticals, INC. | $23.50 | 2025 | |
| Nxstage Medical, INC. | $20.74 | 2025 | Liberty Select Cycler, Pureflow Sl, Nxstage System One |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.